At a glance
- Ularitide is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 281 publications mentioning it, including 34 randomized controlled trials and 72 animal-only studies.
- ClinicalTrials.gov lists 4 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Urinary urodilatin levels in patients with renal salt wasting syndrome as a possible new diagnostic marker. A pilot study.
- (Pro)renin, Erythropoietin, Vitamin D and Urodilatin Release From Human Donor Kidneys During Normothermic Machine Perfusion: Predictors of Early Post-Transplant Outcome?
- Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites.
- New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review.
- Human Transplant Kidneys on Normothermic Machine Perfusion Display Endocrine Activity.
- The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects.
- Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis.
- Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis.
- Modified natriuretic peptides and their potential roles in cancer treatment.
- Ularitide as treatment of refractory ascites in cirrhosis- a study protocol for a randomised trial.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 4
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide. | Terminated | Phase 2 | August 1, 2020 |
| Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure | Completed | Phase 3 | Jul 2012 |
| Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol | Completed | Phase 2 | Jul 2003 |
| A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure | Withdrawn | Phase 1 | — |
All 4 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.